This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Synthetic marijuana

Authoring team

Synthetic cannabis (synthetic marijuana), or technically synthetic cannabinoid receptor agonists, are any drug that mimics the effects of cannabis sprayed onto a herbal base material. Synthetic cannabis is often termed spice product.

Notice was given at the end of 2010 by the Drug Enforcement Agency (DEA) that five members of the "synthetic cannabinoids" group or "Spice" compounds were to be banned in the U.S

  • the substances were:
    • 1-pentyl-3-(1-naphthoyl)- indole (JWH-018),
    • 1-butyl-3-(1-naphthoyl)-indole (JWH-073),
    • 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)-indole (JWH-200),
    • 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- phenol (CP-47497),
    • and 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47497 C8 homologue)

  • the drugs have been described by users as having cannabis-like effects, and some of these compounds show strong binding to cannabinoid receptors. In general plant materials are sprayed with one or a combination of these synthetic compounds before sale.

According to the Drug Enforcement Agency, K2 and Spice has street names such as "Bliss", "Black Mamba", "Bombay Blue", "Fake Weed", "Genie", and "Yucatan Fire" among others, and compounds typically detected in the mixes include JWH-018, JWH-073, and HU-210 and its non-pharmacologically active enantiomer HU-211.

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.